User profiles for Mikko Niemi

Mikko Niemi

Professor of Pharmacogenetics
Verified email at helsinki.fi
Cited by 22754

Drug interactions with lipid‐lowering drugs: mechanisms and clinical relevance

PJ Neuvonen, M Niemi… - Clinical Pharmacology & …, 2006 - Wiley Online Library
Lipid‐lowering drugs, especially 3‐hydroxy‐3‐methylglutaryl–coenzyme A inhibitors (statins),
are widely used in the treatment and prevention of atherosclerotic disease. The benefits of …

Impact of OATP transporters on pharmacokinetics

A Kalliokoski, M Niemi - British journal of pharmacology, 2009 - Wiley Online Library
Membrane transporters are now recognized as important determinants of the transmembrane
passage of drugs. Organic anion transporting polypeptides (OATP) form a family of influx …

Pharmacokinetic interactions with rifampicin: clinical relevance

M Niemi, JT Backman, MF Fromm, PJ Neuvonen… - Clinical …, 2003 - Springer
The antituberculosis drug rifampicin (rifampin) induces a number of drug-metabolising enzymes,
having the greatest effects on the expression of cytochrome P450 (CYP) 3A4 in the liver …

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

M Niemi, MK Pasanen, PJ Neuvonen - Pharmacological reviews, 2011 - ASPET
The importance of membrane transporters for drug pharmacokinetics has been increasingly
recognized during the last decade. Organic anion transporting polypeptide 1B1 (OATP1B1) …

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

…, M Neuvonen, PJ Neuvonen, M Niemi - Pharmacogenetics …, 2006 - journals.lww.com
Methods Four healthy volunteers with the homozygous SLCO1B1 c. 521CC genotype, 12
with the heterozygous c. 521TC genotype and 16 with the homozygous c. 521TT genotype (…

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C …

M Niemi, E Schaeffeler, T Lang… - Pharmacogenetics …, 2004 - journals.lww.com
This study aimed to characterize possible relationships between polymorphisms in the drug
transporter genes organic anion transporting polypeptide-C (OATP-C, SLCO1B1), OATP-B (…

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

M Niemi, JT Backman, LI Kajosaari… - Clinical …, 2005 - Wiley Online Library
Background and Objective A large interindividual variability exists in the plasma
concentrations of repaglinide. Our aim was to investigate possible associations between the …

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

…, H Fredrikson, PJ Neuvonen, M Niemi - Clinical …, 2007 - Wiley Online Library
Thirty‐two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of
atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1 week. Subjects with …

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal …

RM Cooper‐DeHoff, M Niemi… - Clinical …, 2022 - Wiley Online Library
Statins reduce cholesterol, prevent cardiovascular disease, and are among the most
commonly prescribed medications in the world. Statin‐associated musculoskeletal symptoms (…

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update

…, L Gong, TE Klein, M Wadelius, M Niemi - Clinical …, 2014 - Wiley Online Library
Simvastatin is among the most commonly used prescription medications for cholesterol
reduction. A single coding single‐nucleotide polymorphism, rs4149056T>C, in SLCO1B1 …